about
Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials.Nutritional advice in older patients at risk of malnutrition during treatment for chemotherapy: a two-year randomized controlled trial.Pseudomonas aeruginosa acquisition on an intensive care unit: relationship between antibiotic selective pressure and patients' environmentOne-Year Mortality in Older Patients with Cancer: Development and External Validation of an MNA-Based Prognostic ScoreFrench multicentre clinical evaluation of helical TomoTherapy for anal cancer in a cohort of 64 consecutive patientsInnovations for phase I dose-finding designs in pediatric oncology clinical trials.Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials.Design of a Physical Activity Program to Prevent Functional Decline in Onco-Geriatric Patients (CAPADOGE): A Randomized Multicenter Trial.Diagnostic and prognostic value of BCL2 rearrangement in 53 patients with follicular lymphoma presenting as primary skin lesions.A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials.[Dose finding methods for targeted agents: new perspectives].Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study.Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial.Impact du statut socioéconomique sur la gravité du diagnostic initial de cancer du sein[Psychiatric adverse effects of fluoroquinolone: review of cases from the French pharmacologic surveillance database]90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomasFresh-frozen plasma transfusion did not reduce 30-day mortality in patients undergoing cardiopulmonary bypass cardiac surgery with excessive bleeding: the PLASMACARD multicenter cohort studyBenefit, burden, and impact for a cohort of post-approval cancer combination trialsComparison between protocols and publications for prognostic and predictive cancer biomarker studies
P50
Q30665810-8A091A7E-CAA0-4A05-ADCA-5D23F80C0BAFQ34274135-5A317EF7-55FF-4B90-8914-B1C858F72780Q35566984-025B5749-AEDA-456C-87D5-2332AB1E518DQ35918084-F42AEEB1-E29F-479E-B4D3-64B258778F60Q36009950-68681EE5-CC2D-4476-859D-6E1893614909Q36757843-6C9E4EAB-233D-42DC-922B-CFB3949CE5D5Q38057500-EAA583B8-00AC-42AA-9C2D-559FDB0DE762Q39839734-E85C95F5-02CD-46EA-9C92-0DE7764141BAQ41390666-F1303DCD-F9D2-4D89-876D-7375E1AC6436Q42697628-5CE08FD1-A19D-49C0-82E1-0598A8337A8BQ42759726-87C9771B-AB3C-484F-88F7-94ACC3261B7DQ44880020-689E1569-C1E2-4492-A068-63DFEE76EA0EQ48377599-E2B03DD9-EB5D-438B-85A1-80251DAF0855Q59220868-947E25E7-4AF1-4BD9-B4D5-EF0F039DCBEAQ83035541-F57DDCFA-214D-43B8-A735-7DFE743E7EF4Q85895522-96244F2B-24EB-4430-A01A-B9FC4E0787BFQ86511819-D76ECC87-E8FE-4698-B45D-434425FFAEDDQ90452555-498BB731-1D77-4C07-9C14-FF0117106A7CQ90546457-8FFA58E3-5A24-4518-AF89-34277832E9DA
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Adélaïde Doussau
@en
Adélaïde Doussau
@nl
type
label
Adélaïde Doussau
@en
Adélaïde Doussau
@nl
prefLabel
Adélaïde Doussau
@en
Adélaïde Doussau
@nl
P31
P496
0000-0003-2622-5948